Dextran 70/hydroxypropyl methylcellulose: Main Uses and Benefits

Dextran 70/hydroxypropyl methylcellulose is an ophthalmic combination product used for the management of dry, irritated eyes. Its primary therapeutic use is the temporary relief of discomfort and symptoms associated with minor eye irritations.

Quick Facts

• Relieves: Dry, irritated eyes.
• Addresses: Temporary discomfort from minor eye irritations.
• Protects Against: Further irritation from environmental exposure, such as wind or sun.

Therapeutic Overview

The formulation functions as an eye lubricant to help maintain moisture on the eye's surface. This lubrication can help protect the eye from injury and reduce symptoms such as burning, itching, and the sensation of having a foreign object in the eye. The product is also indicated for the temporary relief of discomfort due to exposure to environmental elements, including wind or sun.

This section outlines the officially documented population eligibility and non-eligibility rules for Dextran 70/Hydroxypropyl Methylcellulose ophthalmic solution as stated in government regulatory documents.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Age Groups: Use is permitted and established in children, adults, and the elderly.
• Reproductive Status: Use is permitted during both pregnancy and breastfeeding, as negligible systemic absorption means no adverse effects on the fetus or infant are anticipated.
• Systemic Conditions: No restrictions are officially documented in the label for patients with renal or hepatic impairment.

Eligibility-Related Restrictions:

• Soft Contact Lens Wearers: Must remove soft contact lenses before application. A 15-minute waiting period is required before reinsertion to avoid potential lens discoloration or preservative interaction.

Connection to the overall eligibility profile: Official regulatory documents define the product's eligibility based on local factors, limiting the absolute contraindication solely to a known hypersensitivity to any ingredient. Due to its topical application and negligible systemic absorption, this medicine is broadly permitted across all major age and reproductive categories.

Interactions with other medicines and products

Official regulatory documents confirm that Dextran 70/hydroxypropyl methylcellulose, an ocular lubricant, is not expected to cause systemic drug-drug interactions. The active ingredients are pharmacologically inert and exhibit negligible absorption into the bloodstream, meaning they do not participate in metabolic pathways involving enzymes like cytochrome P450 or drug transporters (e.g., P-gp).

Consequently, the interaction profile is limited strictly to physical administration-timing rules for co-administration with other topical eye preparations.

Documented Topical Interaction Rules

Systemic Interaction Summary

No interactions are formally documented in government regulatory sources for this product involving oral or systemic medicines, food, alcohol, or herbal supplements. The absence of systemic interactions is consistent with the product's function as a surface-acting polymer formulation.

Dextran 70 and hydroxypropyl methylcellulose (HPMC) function primarily as topical agents affecting the viscosity and adherence properties within the target tissue environment. Dextran 70 is a high-molecular-weight polysaccharide that, when applied, increases the viscoelasticity of the surface medium. This action facilitates a physical, protective layer through mucoadhesion, modifying the shear forces exerted on the tissue epithelium. HPMC, a cellulose derivative, complements this function by contributing to the formation of a stabilized, high-molecular-weight mesh structure. This mesh increases the residence time of the solution on the targeted surface. Mechanistically, this sustained physical presence modulates the local fluid dynamics and alters the osmotic characteristics at the epithelial interface. The collective action of these polymers establishes a localized physical barrier that modifies the physiological interaction between the tissue surface and the surrounding external environment. This modification is purely biophysical and does not involve specific receptor binding, enzyme inhibition, or modulation of intracellular signaling cascades.

How to Use Dextran 70/Hydroxypropyl Methylcellulose

Dextran 70/hydroxypropyl methylcellulose is administered via the ophthalmic route as an aqueous solution applied directly to the affected eye(s). The product is designated solely for external use, establishing a clear boundary for its intended site of administration.

The established dosing regimen involves administering one or two drops per application into the affected eye(s). The frequency is defined as as needed (PRN), which dictates a symptom-driven, intermittent usage pattern rather than a mandatory, fixed daily schedule. The overall use pattern is consequently one of temporary support, not continuous therapeutic intervention.

Proper application protocol mandates specific procedural steps for safe and effective administration. Contact lenses must be removed prior to instillation of the drops. To maintain the integrity of the solution and prevent contamination, the container tip must not be allowed to touch any surface, including the eye or hands, during the process; the cap must be securely replaced immediately after use.

The standard dosing parameters apply to the general adult population and to children aged six years and older. For administration to children under six years of age, the label states that a doctor must be consulted before initiation of use.

Research evidence / Overview of studies for Dextran 70/hydroxypropyl methylcellulose

Evidence for Use in Dry Eye Syndrome and General Ocular Discomfort

This combination of Dextran 70 and Hydroxypropyl Methylcellulose (HPMC) was studied in research exploring how symptoms change over time in individuals presenting with conditions characterized by fluctuating or episodic manifestations of dry eye syndrome. Research was primarily conducted through short-term Randomized Controlled Trials (RCTs), where this solution was compared against other common lubricating eye drops and non-active solutions, such as saline. These trials involved adult patients with established dry eye conditions and outcomes related to physical discomfort were measured, along with changes in the eye's physical status.

Researchers examined patient-reported outcomes describing perceived discomfort (such as burning, grittiness, and overall dryness scores) and objective outcomes like the stability of the tear film (Tear Break-up Time or TBUT). Studies monitored patterns of change in subjective symptom scores across the study period. However, when studies monitored objective measurements of the eye's surface integrity, the findings were mixed, with some showing differences and others reporting non-significant changes when compared to other treatments or baseline status.

Evidence for Use Following Eye Surgery

Research has explored the role of this formulation in the post-operative setting following specific surgical procedures. Clinical investigations and smaller comparative studies monitored its use as a lubricating solution during the initial recovery period following common eye procedures like LASIK and cataract surgery. The solution was observed in some studies as a comparator lubricating solution or control group in research examining temporary physiological imbalance.

Long-term Follow-up and Duration of Effect Studies

The majority of clinical trials for this combination solution were designed to study short-term symptom patterns. The duration of follow-up in the primary intervention studies was limited, typically lasting two to four weeks. There is limited information for long-term outcomes, as the effects of the combination solution on the ocular surface status beyond the initial short period are not fully established in the available published trials.

What Research Gaps and Uncertainty Remain

The overall research describing the patterns of change for this class of medicine is subject to significant methodological heterogeneity. Specific points of uncertainty documented in the scientific literature include:

• Comparative evidence is lacking to definitively suggest that this Dextran 70/HPMC combination or any other specific artificial tear agent is superior to another for the overall management of dry eye disease.
• Results apply only to the populations studied, and data for certain groups (such as those with severe, chronic dry eye) remain insufficient or uncertain.

Key Studies & References

1. The International Dry Eye Workshop (DEWS) II Report
2. MedlinePlus Drug Information: Dextran 70 / Hydroxypropyl Methylcellulose Ophthalmic

Common questions about Dextran 70/hydroxypropyl methylcellulose (FAQ)

Q: How long after putting in the drops does the temporary blurred vision last?

Regulatory documents state that temporary blurred vision is a common effect immediately following instillation of the eye drops. Since this effect can briefly impact vision, official information advises that individuals typically wait until their vision is completely clear before activities like driving or operating machinery.

Q: What should I do if I accidentally swallow Dextran 70/Hydroxypropyl Methylcellulose solution?

Official product information states that if the solution is accidentally swallowed, professional medical assistance or contact with a Poison Control Center should be sought immediately. This information is consistent with regulatory guidelines for oral ingestion.

Q: Can I use these drops to treat an eye infection like conjunctivitis ('pink eye')?

According to the official product information, this solution is used for the temporary relief of discomfort associated with minor eye irritations or dry eyes. The labeling advises that if symptoms such as redness or irritation persist or worsen, use should be discontinued and a doctor consulted, as these can be signs of an underlying condition, such as an eye infection.

Q: Is there any danger if the product is accidentally frozen?

Official storage instructions indicate that this medicine must be stored at room temperature and must not be frozen. The product label states that the solution should not be used if it has been frozen or if there are any changes to its appearance, such as discoloration or becoming cloudy.

Q: How do I know if I am having a hypersensitivity or allergic reaction to the eye drops?

Hypersensitivity (a severe allergic reaction) to the ingredients is listed as a possible adverse reaction. Official labeling advises that if an individual experiences symptoms like eye pain, changes in vision, or a rash, use should be stopped, and medical attention should be sought immediately, as these can be signs of a serious hypersensitivity reaction.

Storage and Disposal of Dextran 70/Hydroxypropyl Methylcellulose Ophthalmic Solution

The storage and disposal of this ophthalmic solution must follow official regulatory labeling to ensure product stability and safety.

Storage Conditions and Stability

The medicine must be stored at room temperature, typically 15 C to 30 C (59 F to 86 F), and must not be frozen. It must be protected from direct light, heat, and moisture.

• The container tip must not touch any surface to maintain sterility, and the cap must be replaced tightly after each use.
• Multi-dose bottles should be discarded 28 days after opening, or as directed by the product label. Single-use vials must be discarded immediately after use and not reused.

Disposal and Child Safety

The solution must be kept out of the sight and reach of children at all times.

• Disposal of expired or unused product should not be done via the toilet or drain unless specific instructions from an authorized take-back program are provided. Dispose of the medication according to the guidance of a pharmacist or local waste disposal company.